Physician profile
Sofia Grewal
NPI 1265441299
$4,361.54
in general payments reported to CMS, 2019-2025
25 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $536 · 2021: $322 · 2022: $740 · 2023: $1,219 · 2024: $1,026 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,308.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.99 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $456.18 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $453.02 | 2022-2024 | Qelbree, Qelbree |
| Allergan, INC. | $424.76 | 2019-2020 | |
| Axsome Therapeutics, INC. | $312.88 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $288.16 | 2019-2022 | |
| Alkermes, INC. | $233.46 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $226.76 | 2020-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $180.56 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.21 | 2021-2024 | Caplyta |
| Sumitomo Pharma America, INC. | $125.00 | 2024 | Gemtesa |
| Vanda Pharmaceuticals INC. | $121.45 | 2019-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $106.67 | 2024 | Quviviq |
| Lundbeck LLC | $104.39 | 2023-2025 | Rexulti |
| Corium, LLC | $87.84 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $83.62 | 2023-2024 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $80.17 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.32 | 2021-2022 | |
| Tris Pharma INC | $75.12 | 2023-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $47.86 | 2022-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $34.96 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $21.45 | 2023 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $20.43 | 2025 | Jornay Pm |
| Neos Therapeutics, Lp | $16.21 | 2024 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $14.07 | 2023 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Grewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.